Culotte Versus DK-CRUSH Technique in Non-left Main Coronary Bifurcation Lesions (BBK-3)

August 4, 2022 updated by: Dr. Miroslaw FERENC, University Heart Center Freiburg - Bad Krozingen

Bifurcations Bad Krozingen (BBK) 3 - Trial Randomised Comparison of Culotte-stenting Versus DK-Crush--stenting for the Treatment of de Novo Non-left Main Coronary Bifurcation Lesions With Everolimus-eluting Stents

Randomised comparison of Culotte technique versus "Double Kissing" - Crush technique (DK-Crush) for the percutaneous treatment of de novo non-left main coronary bifurcation lesions with modern everolimus-eluting stents (DES) - German multicenter study

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Aim of study This prospective randomized multicenter study will compare the long-term safety and efficacy of Culotte stenting versus "Double Kissing" - Crush (DK-Crush) stenting in the treatment of the de-novo non-left main coronary bifurcation lesions with new generation everolimus-eluting stents.

Study hypothesis In large coronary bifurcation lesions (main vessel > 2.5mm, side branch > 2.25mm) including significant ostial side branch disease, Culotte stenting compared with DKcrush stenting reduces maximal percent diameter stenosis at the bifurcation at 9-month follow-up by 25 %.

Study design Prospective, randomized, German multicenter study.

Methods Four-hundred patients, in whom a double-stenting technique is intended for the treatment of a non-left main de-novo coronary bifurcation lesion will be randomly assigned to Culotte stenting or to DK-crush stenting with an approved drug-eluting stent (SYNERGY-Stent). As a part of usual care, patients will undergo 9-month angiographic follow-up with quantitative coronary angiography. Clinical follow-up is planned at 1 year if no angiographic follow-up is obtained.

Study Type

Interventional

Enrollment (Anticipated)

400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Bad Oeynhausen, Germany, 32545
        • Recruiting
        • Herz-u. Diabeteszentrum
      • Bad Segeberg, Germany, 23795
        • Recruiting
        • Herz-Und Gefasszentrum
      • Dortmund, Germany, 44137
        • Recruiting
        • St. Johannes-Hospital
      • Dresden, Germany, 01307
        • Recruiting
        • Herzzentrum Dresden an der Technischen Universität
      • Essen, Germany, 45138
        • Recruiting
        • Elisabeth Krankenhaus
      • Gießen, Germany, 35392
        • Recruiting
        • Universitätsklinikum Gießen
      • Leipzig, Germany, 04103
        • Recruiting
        • Universitätsklinikum Leipzig
      • Mannheim, Germany, 68167
        • Recruiting
        • Universitätsklinik Mannheim
      • München, Germany, 80636
        • Recruiting
        • Deutsches Herzzentrum
      • Oldenburg, Germany, 26133
        • Recruiting
        • Klinikum Oldenburg
      • Trier, Germany, 54292
        • Recruiting
        • Herzzentrum Trier
      • Ulm, Germany, 89070
        • Recruiting
        • Universitatsklinikum Ulm
    • Suedring 15

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Clinical indication, evidenced by angina / angina-equivalent symptoms or documented ischemia (non-invasive imaging such as scintigraphy, stress-MRI or stress-echo; FFR or iwFR) or patients with acute coronary syndromes (NSTE-ACS).
  2. Clinical indication to perform double stenting only with Synergy™ stents for a clinically significant bifurcation stenosis as judged by the operator.
  3. De-novo non-Ieft main coronary bifurcation lesions - 1,1,1 or 0,1,1 according to the Medina classification - of a native coronary artery with the following reference vessel diameters: main branch > 2,5 mm; side branch > 2,25 mm. The difference between vessel diameter of the main and side branch is ≤ 1 mm.
  4. The target lesion has not been previously treated with any interventional procedure.
  5. The target vessel (main branch and side branch) must appear feasible for stent implantation.
  6. Patient has no other coronary intervention planned within 30 days of the procedure.
  7. Patient has been informed of the nature of the study and agrees to its provisions and has written informed consent as approved by the Ethics Committee.
  8. Patient is willing to comply with all required post-procedure follow-up.

Exclusion Criteria:

  1. Patient had an acute ST-elevation myocardial infarction within 72 h preceding the index procedure or target vessel contains intraluminal thrombus.
  2. Use of any other coronary stent than Synergy™ and Synergy Megatron™ except for baiI-out situations.
  3. Patient with a known hypersensitivity or contraindication to the needed antithrombotic therapy, stent type or contrast media that cannot be adequately pre-medicated.
  4. Non successful treatment of other lesion during the same procedure.
  5. Patient with a severe bleeding diathesis, history of recent major bleeding or stroke (≤ 6 months), coagulopathy or severe liver disease.
  6. Patient has a co-morbidity (i.e. cancer) that may cause the patient to be noncompliant with the protocol, or is associated with limited life-expectancy (Iess than 1 year).
  7. Patient is participating in any other clinical study with an investigational product.
  8. Patient is known to be pregnant or lactating at time of inclusion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Culotte Technique
Both vessels have to be wired. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference. After lesion preparation, the side branch has to be stented first. The first stent is placed from main branch into the side branch, covering the entire diseased segment with a wire jailed in the main vessel. The main vessel is rewired through the stent struts, and after removal of the jailed wire, is dilated with a balloon to separate stent struts. The side branch wire is then removed and the main vessel is stented covering the proximal and distal segment. The side-branch is re-wired and high pressure individual inflations are made in each vessel at the bifurcation point to ensure good stent strut separation. Afterwards, a lower pressure kissing inflation is made. Balloon sizing should be in accordance with the diameter of the vessel itself. Finally, a proximal optimization (POT) procedure is performed.
Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions
Active Comparator: DK-Crush Technique

Both vessels have to be wired first. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference (rotablation, if needed).

After lesion preparation, the side branch is stented first. Side branch stent should have a small protrusion into the main branch. Before stent implantation in the side branch, an adequately sized balloon should be placed in the main branch, just opposite to the side branch ostium. After stent implantation in the side branch, stent balloon and wire are removed and the balloon in the main branch must be inflated, to crush the struts into the vessel wall. In next step, the new wire should be crossed into the ostium of the side branch and first kissing balloon dilatation will follow. The next step is to implant the second stent into the main branch, followed by second re-wiring, a second kissing balloon-dilatation and final proximal optimization (POT) procedure (single short balloon inflation in proximal segment).

Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Angiographic restenosis in the bifurcation lesion by quantitative coronary analysis (QCA)
Time Frame: 9 months post index percutaneous coronary intervention (PCI)

For quantitative coronary angiography, changes between result at the completion of the index intervention and at 9 months follow-up will be analysed using a computer based system dedicated to bifurcation analysis, according to the standard operating procedure of the angiographic core laboratory.

Quantitative angiographic measurements will be obtained of the three segments of the bifurcation lesion: the proximal and distal segment of the main branch and the side branch. We will perform measurements in the stented portion of the vessel (in-stent) and in the distal or proximal 5 mm margin (edge). In-segment analyses will comprise the in-stent and the edge area.

In addition, the bifurcation angle from the analysis system will be estimated.

9 months post index percutaneous coronary intervention (PCI)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of target lesion revascularisation (TLR)
Time Frame: 1 year
Any revascularisation (Re-PCI or CABG) at segments treated during index procedure
1 year
Incidence of major adverse cardiac events (MACE)
Time Frame: 1 year
MACE defined as death, Myocardial infarction (Q wave and Non-Q wave), emergent cardiac bypass surgery, or TLR
1 year
Incidence of binary restenosis at any segment of the bifurcation lesion
Time Frame: 9 months
≥ 50% diameter stenosis in the main and side branch
9 months
Incidence of binary restenosis in the main and side branch
Time Frame: 9 months
≥ 50% diameter stenosis in main and side branch
9 months
Incidence of stent thrombosis (ST)
Time Frame: 1 year
Post-procedure thrombotic stent occlusion according to the Academic Research Consortium-criteria
1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of device success
Time Frame: 9 months
Attainment of < 30% residual stenosis of the target lesion in the main and side branch
9 months
Mean procedure time
Time Frame: Index Intervention
Procedure time measured in minutes
Index Intervention
Mean radiation exposure
Time Frame: Index Intervention
Radiation exposure measured in cGym²
Index Intervention
Mean volume of used contrast medium
Time Frame: Index Intervention
Contrast medium measured in milliliters
Index Intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2019

Primary Completion (Anticipated)

March 31, 2023

Study Completion (Anticipated)

December 31, 2023

Study Registration Dates

First Submitted

November 27, 2019

First Submitted That Met QC Criteria

December 9, 2019

First Posted (Actual)

December 10, 2019

Study Record Updates

Last Update Posted (Actual)

August 5, 2022

Last Update Submitted That Met QC Criteria

August 4, 2022

Last Verified

August 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Stenosis

Clinical Trials on Stenting

3
Subscribe